GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » OncoCyte Corp (STU:7OC0) » Definitions » EV-to-EBITDA
中文

OncoCyte (STU:7OC0) EV-to-EBITDA

: -2.45 (As of Today)
View and export this data going back to 2018. Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, OncoCyte's enterprise value is €24.58 Mil. OncoCyte's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-10.04 Mil. Therefore, OncoCyte's EV-to-EBITDA for today is -2.45.

The historical rank and industry rank for OncoCyte's EV-to-EBITDA or its related term are showing as below:

STU:7OC0' s EV-to-EBITDA Range Over the Past 10 Years
Min: -81.06   Med: -2.75   Max: 42.36
Current: -2.39

During the past 11 years, the highest EV-to-EBITDA of OncoCyte was 42.36. The lowest was -81.06. And the median was -2.75.

STU:7OC0's EV-to-EBITDA is ranked worse than
100% of 117 companies
in the Medical Diagnostics & Research industry
Industry Median: 15.41 vs STU:7OC0: -2.39

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-24), OncoCyte's stock price is €3.34. OncoCyte's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-3.271. Therefore, OncoCyte's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


OncoCyte EV-to-EBITDA Historical Data

The historical data trend for OncoCyte's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoCyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.11 -5.44 -3.55 -1.59 -0.61

OncoCyte Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.59 -81.08 43.67 8.31 -0.61

Competitive Comparison

For the Diagnostics & Research subindustry, OncoCyte's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoCyte EV-to-EBITDA Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, OncoCyte's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where OncoCyte's EV-to-EBITDA falls into.



OncoCyte EV-to-EBITDA Calculation

OncoCyte's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=24.576/-10.04
=-2.45

OncoCyte's current Enterprise Value is €24.58 Mil.
OncoCyte's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-10.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoCyte  (STU:7OC0) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

OncoCyte's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.34/-3.271
=At Loss

OncoCyte's share price for today is €3.34.
OncoCyte's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.271.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


OncoCyte EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of OncoCyte's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoCyte (STU:7OC0) Business Description

Traded in Other Exchanges
Address
15 Cushing, Irvine, CA, USA, 92618
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States.

OncoCyte (STU:7OC0) Headlines

No Headlines